Product image of Mikofenolatna Kiselina Accord (Mycophenolic Acid) supplied by GNH India

Mikofenolatna Kiselina Accord

Active Ingredient:
Mycophenolic Acid
Origin:
EU

Mikofenolatna Kiselina Accord (Mycophenolic Acid)

Mycophenolic Acid, the active ingredient in Mikofenolatna Kiselina Accord, is an immunosuppressant presented as an oral formulation for oral use. It is employed to prevent organ transplant rejection and to treat lupus nephritis by suppressing immune cell activity.

GNH India supplies Mikofenolatna Kiselina Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and pharmacies worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution. Clients benefit from consistent product availability and regulatory compliance support.

Manufacturer / TM Owner

Accord Healthcare Polska Sp. Z O.O.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Mycophenolic Acid is used to manage immune‑mediated conditions, particularly in transplant and autoimmune disease contexts.

  • Organ transplant rejection: reduces the risk of acute rejection in kidney, heart and liver transplants.
  • Lupus nephritis: helps control renal inflammation in systemic lupus erythematosus.
  • Graft‑versus‑host disease prophylaxis: used to prevent GVHD in bone marrow transplantation.

How It Works

  • Mycophenolic Acid selectively and reversibly inhibits inosine monophosphate dehydrogenase (IMPDH), the key enzyme for guanosine nucleotide synthesis in lymphocytes. This inhibition limits guanosine pools, thereby suppressing proliferation of T‑ and B‑lymphocytes and reducing immune responses that can lead to graft rejection or autoimmune damage.

Side Effects

Adverse reactions may vary in frequency and severity.

Common Side Effects

  • Nausea: mild to moderate gastrointestinal upset.
  • Diarrhea: loose stools that may affect hydration.
  • Headache: transient cranial discomfort.
  • Infections: increased susceptibility to bacterial, viral or fungal infections.
  • Leukopenia: reduced white blood cell count.
  • Hypertension: elevated blood pressure readings.

Serious or Rare Side Effects

  • Severe infection: opportunistic infections requiring immediate medical attention.
  • Malignancy: potential increased risk of certain cancers with long‑term use.
  • Bone marrow suppression: pancytopenia or aplastic anemia.
  • Hepatic toxicity: elevated liver enzymes or hepatitis.
  • Progressive multifocal leukoencephalopathy (PML): rare viral brain infection.
  • Severe hypersensitivity: rash, angioedema or anaphylaxis.

Precautions & Warnings

Patients should be monitored regularly for safety and efficacy.

  • Blood counts: perform routine complete blood count monitoring.
  • Renal function: assess serum creatinine and glomerular filtration rate.
  • Live vaccines: avoid administration while on therapy.
  • Pregnancy: discuss potential risks with a healthcare professional before use.
  • Hepatic impairment: consider dose adjustment in patients with liver disease.
  • Store at ambient temperature: keep in original packaging, protect from moisture and direct sunlight.

Avoid Interactions

Potential drug interactions may affect efficacy or safety.

Major Interactions (Avoid)

  • Antacids containing aluminum or magnesium: may reduce absorption of the drug.
  • Azathioprine: combined immunosuppression can increase risk of bone marrow suppression.
  • Live vaccines: may lead to severe infection due to immunosuppression.

Moderate Interactions (Monitor Closely)

  • Rifampin: may decrease plasma concentrations of Mycophenolic Acid.
  • Valganciclovir: may increase risk of cytopenias.
  • Cyclosporine or tacrolimus: may require dose adjustments and close therapeutic drug monitoring.

Frequently Asked Questions

Mikofenolatna Kiselina Accord contains Mycophenolic Acid, an immunosuppressant prescribed to prevent organ transplant rejection and to treat lupus nephritis by inhibiting the proliferation of immune cells that can damage transplanted tissue or kidney structures.

Mycophenolic Acid blocks the enzyme inosine monophosphate dehydrogenase (IMPDH), which is essential for guanosine nucleotide synthesis in lymphocytes. By limiting guanosine, it reduces T‑ and B‑cell proliferation, thereby dampening the immune response that can cause graft rejection or autoimmune kidney inflammation.

The dosage of Mycophenolic Acid is individualized by the prescribing clinician based on the specific indication, patient weight, renal function and concomitant therapies. Only a qualified healthcare professional should determine the appropriate regimen.

Safety in pregnancy and lactation has not been fully established. Physicians should evaluate the potential benefits against possible risks, and women of childbearing potential should use effective contraception while on therapy. Breastfeeding decisions should be made in consultation with a healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Mycophenolic Acid differs from calcineurin inhibitors such as cyclosporine or tacrolimus by targeting nucleotide synthesis rather than calcineurin signaling. It offers a distinct side‑effect profile, often with less nephrotoxicity, but may cause more gastrointestinal upset and bone‑marrow suppression, making choice dependent on patient‑specific factors.

Store the product at ambient temperature, below 25 °C, in its original container. Keep it away from moisture, direct sunlight and sources of heat to maintain stability and potency throughout its shelf life.

The medication is taken orally, usually as tablets or capsules, with or without food as directed by the prescriber. Patients should follow the exact dosing schedule provided and not alter the regimen without medical advice.

Serious risks include severe infections, opportunistic pathogens, bone‑marrow suppression leading to pancytopenia, hepatic toxicity, and a potential increased risk of malignancies with long‑term use. Prompt medical evaluation is essential if signs of infection, abnormal bleeding or liver dysfunction appear.

Patients with known hypersensitivity to Mycophenolic Acid or any component of the formulation should avoid the product. It is also contraindicated in individuals with uncontrolled severe infections, active malignancy, or those receiving live vaccines while immunosuppressed.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Mycophenolic Acid

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT